NVO — Novo Nordisk A/S Share News
0.000.00%
Last trade - 00:00- $175.03bn
- $189.31bn
- DKK309.06bn
Factbox: Major drugmakers turn to China for licensing deals
Trump Medicare drug pricing model may apply to only four companies after exemptions
Brief: Novo's Wegovy Reduced Liver Fat To Normal Levels In 88.5% Of Obese Adults With Excess Liver Fat At Week 72
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial (updated)
Regeneron drug halves muscle loss in combination with Novo's semaglutide in trial
Experimental Lilly combination drug tops Zepbound in weight-loss trial (updated)
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Experimental Lilly combination drug tops Zepbound in weight-loss trial
Brief: Novo Nordisk CagriSema Reduced Food Noise, Brain Response to High-Calorie Foods in Obesity Study
Factbox: Major drugmakers turn to China for licensing deals
Advisory: Alert wrongly tagged to Rubicon Organics withdrawn
Brief: Ro Announces Research Collaboration With Novo On Wegovy Pill
Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study
US says two Indian nationals indicted in counterfeit Ozempic smuggling scheme (updated)
Two Indian nationals indicted in counterfeit Ozempic smuggling scheme, Justice Department says
Brief: Novo Says Ozempic Cuts Risk Of Major Cardiovascular Events
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro (updated)
Lilly touts Foundayo advantage over Novo's Ozempic pill in diabetes analysis
Novo Nordisk says Ozempic shows lower risk of cardiovascular events compared to Eli Lilly's Mounjaro